201 related articles for article (PubMed ID: 31129971)
1. Diagnosis and treatment of juvenile myelomonocytic leukemia in Slovak Republic: novel approaches.
Fabri O; Horakova J; Bodova I; Svec P; Laluhova Striezencova Z; Bubanska E; Cermak M; Galisova V; Skalicka K; Vaska A; Doczyova D; Panikova A; Sykora T; Adamcakova J; Kolenova A
Neoplasma; 2019 Sep; 66(5):818-824. PubMed ID: 31129971
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and treatment of juvenile myelomonocytic leukemia.
Sakashita K; Matsuda K; Koike K
Pediatr Int; 2016 Aug; 58(8):681-90. PubMed ID: 27322988
[TBL] [Abstract][Full Text] [Related]
3. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
Locatelli F; Algeri M; Merli P; Strocchio L
Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
[TBL] [Abstract][Full Text] [Related]
4. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
Sakashita K
Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
[TBL] [Abstract][Full Text] [Related]
5. [Successful second allogeneic hematopoietic stem cell transplantation with azacitidine as bridging therapy for relapsed juvenile myelomonocytic leukemia].
Oshiro T; Hyakuna N; Abe H; Hamada S; Nakanishi K
Rinsho Ketsueki; 2023; 64(3):187-192. PubMed ID: 37019671
[TBL] [Abstract][Full Text] [Related]
6. Combination of DNA-hypomethylating agent and hematopoietic stem cell transplantation in treatment of juvenile myelomonocytic leukemia: A case report.
Ai Y; Lu X; Zhu T; Zhu Y; Liu H; Sun S
Medicine (Baltimore); 2020 Dec; 99(50):e23606. PubMed ID: 33327329
[TBL] [Abstract][Full Text] [Related]
7. Juvenile myelomonocytic leukemia: epidemiology, etiopathogenesis, diagnosis, and management considerations.
Yoshimi A; Kojima S; Hirano N
Paediatr Drugs; 2010; 12(1):11-21. PubMed ID: 20034338
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
[TBL] [Abstract][Full Text] [Related]
9. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
Niemeyer CM; Flotho C; Lipka DB; Starý J; Rössig C; Baruchel A; Klingebiel T; Micalizzi C; Michel G; Nysom K; Rives S; Schmugge Liner M; Zecca M; Schönung M; Baumann I; Nöllke P; Benettaib B; Biserna N; Poon J; Simcock M; Patturajan M; Menezes D; Gaudy A; van den Heuvel-Eibrink MM; Locatelli F
Blood Adv; 2021 Jul; 5(14):2901-2908. PubMed ID: 34297046
[TBL] [Abstract][Full Text] [Related]
10. Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia.
Marcu A; Colita A; Radu LE; Jercan CG; Bica AM; Asan M; Coriu D; Tanase AD; Diaconu CC; Mambet C; Botezatu A; Pasca S; Teodorescu P; Anton G; Gurban P; Colita A
Front Oncol; 2020; 10():484. PubMed ID: 32328464
[No Abstract] [Full Text] [Related]
11. [Clinical features and prognosis of juvenile myelomonocytic leukemia: an analysis of 63 cases].
Yang WY; Liu LP; Liu F; Qi BQ; Chang LX; Zhang L; Chen XJ; Zou Y; Chen YM; Guo Y; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Mar; 25(3):265-271. PubMed ID: 36946161
[TBL] [Abstract][Full Text] [Related]
12. Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.
Hashmi SK; Punia JN; Marcogliese AN; Gaikwad AS; Fisher KE; Roy A; Rao P; Lopez-Terrada DH; Ringrose J; Loh ML; Niemeyer CM; Rau RE
Pediatr Blood Cancer; 2019 Oct; 66(10):e27905. PubMed ID: 31250550
[TBL] [Abstract][Full Text] [Related]
13. A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.
Honda Y; Muramatsu H; Nanjo Y; Hirabayashi S; Meguro T; Yoshida N; Kakuda H; Ozono S; Wakamatsu M; Moritake H; Yasui M; Sano H; Manabe A; Sakashita K
Int J Hematol; 2022 Feb; 115(2):263-268. PubMed ID: 34714526
[TBL] [Abstract][Full Text] [Related]
14. Juvenile Myelomonocytic Leukemia in Turkey: A Retrospective Analysis of Sixty-five Patients.
Tüfekçi Ö; Koçak Ü; Kaya Z; Yenicesu İ; Albayrak C; Albayrak D; Yılmaz Bengoa Ş; Patıroğlu T; Karakükçü M; Ünal E; Ünal İnce E; İleri T; Ertem M; Celkan T; Özdemir GN; Sarper N; Kaçar D; Yaralı N; Özbek NY; Küpesiz A; Karapınar T; Vergin C; Çalışkan Ü; Tokgöz H; Sezgin Evim M; Baytan B; Güneş AM; Yılmaz Karapınar D; Karaman S; Uygun V; Karasu G; Yeşilipek MA; Koç A; Erduran E; Atabay B; Öniz H; Ören H
Turk J Haematol; 2018 Mar; 35(1):27-34. PubMed ID: 28179213
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
Koike K; Matsuda K
Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
[TBL] [Abstract][Full Text] [Related]
16. Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.
Loh ML
Hematology Am Soc Hematol Educ Program; 2010; 2010():357-62. PubMed ID: 21239819
[TBL] [Abstract][Full Text] [Related]
17. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
18. Juvenile myelomonocytic leukemia-A comprehensive review and recent advances in management.
Gupta AK; Meena JP; Chopra A; Tanwar P; Seth R
Am J Blood Res; 2021; 11(1):1-21. PubMed ID: 33796386
[TBL] [Abstract][Full Text] [Related]
19. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
Yoshida N; Doisaki S; Kojima S
Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of Gene Mutation and Clinical Characteristics in 19 Children with Juvenile Myelomonocytic Leukemia].
Weng KZ; Zheng YZ; Zhuang SQ; Chen HY; LE SH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1811-1818. PubMed ID: 33283703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
